CoChat

Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology

Lim, Bryant, Sproule, Beth A., Zahra, Zarin, Sunderji, Nadiya, Kennedy, Sidney H., Rizvi, Sakina J. · 2020 · International Clinical Psychopharmacology

The DOI matches its Crossref record; 173 of the 178 references it cites were found in a registry or an index.

Abstract

Benzodiazepines are frequently prescribed on an ongoing basis to individuals with depression, mainly to alleviate anxiety or insomnia, despite current guideline recommendations that continuous use should not exceed 4 weeks. Currently, there are no efficacy trials published beyond 8 weeks. Several antidepressant trials demonstrate that the concomitant use of a benzodiazepine is associated with poorer depressive outcomes and functional status; however, it is unclear why this is the case. Patients with depression receiving a benzodiazepine may reflect a more ill or high anxiety group, although even within anxiety disorders, the use of a benzodiazepine is associated with poorer outcomes. The neuroadaptive consequences of long-term benzodiazepine use may be a factor underlying these findings. Chronic benzodiazepine use results in decreased gamma-aminobutyric acid and monoaminergic function, as well as interference with neurogenesis, which are all purported to play a role in antidepressant efficacy. This review will discuss the oppositional neuropharmacological interactions between chronic benzodiazepine use and antidepressant mechanism of action, which could result in reduced antidepressant efficacy and function in depression.

Overview

Integrity signals

Registry

Crossref · 10.1097/yic.0000000000000316

Cites

173 of 173 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 173 references

Research works printed but not linked: 2

  1. Furukawa, 2002, Antidepressant and benzodiazepine for major depression., Cochrane Database Syst Rev, 1, CD001026
  2. Mbomo, 2011, Effect of Mimosa pudica (Linn.) extract on anxiety behavior and GABAergic regulation of 5-HT neuronal activity in the mouse., J Psychopharmacol, 26, 573

Cited by

See all 60

Metadata

Authors
Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., & Rizvi, S. J.
Affiliations
  • St. Michael's Hospital (CA)
  • Centre for Addiction and Mental Health (CA)
  • Waypoint Centre for Mental Health Care (CA)
Corresponding author
Rizvi, Sakina J.
Venue
International Clinical Psychopharmacology
Published
2020-05-25
Volume
35
Issue
5
Pages
243-253
ISSN
0268-1315 (ISSN-L)
OpenAlex
W3031969505
Cited by
50
References
178
Citations by year
2026: 8 · 2025: 7 · 2024: 15 · 2023: 10 · 2022: 5 · 2021: 3 · 2020: 2
FWCI
0.65
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
chronic benzodiazepine use, depression, antidepressant efficacy, GABAergic function, neurogenesis, anxiety, insomnia, functional outcome
MeSH terms
Anxiety, Benzodiazepines, Central Nervous System, Depression, Humans, Anti-Anxiety Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. https://app.cochat.ai/papers/10.1097/yic.0000000000000316
The paper
Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., & Rizvi, S. J. (2020). Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000316

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.